FY2026 EPS Estimate for Krystal Biotech Boosted by Analyst

Krystal Biotech, Inc. (NASDAQ:KRYS) – HC Wainwright boosted their FY2026 earnings per share estimates for shares of Krystal Biotech in a report released on Monday, August 3rd. HC Wainwright analyst J. Pantginis now anticipates that the company will earn $7.10 per share for the year, up from their previous estimate of $6.83. HC Wainwright currently has a “Buy” rating and a $361.00 target price on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $7.31 per share. HC Wainwright also issued estimates for Krystal Biotech’s FY2027 earnings at $6.80 EPS and FY2028 earnings at $11.97 EPS.

Other equities research analysts have also issued research reports about the stock. Weiss Ratings lowered shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, July 1st. Wall Street Zen cut Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Evercore restated an “outperform” rating and set a $300.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 5th. Jefferies Financial Group restated a “buy” rating and set a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. Finally, Citigroup reaffirmed a “buy” rating on shares of Krystal Biotech in a research report on Tuesday. Ten analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Krystal Biotech has an average rating of “Moderate Buy” and an average target price of $360.67.

Krystal Biotech Trading Down 8.4%

Shares of KRYS opened at $312.57 on Tuesday. The stock has a 50 day moving average of $339.96 and a 200-day moving average of $296.59. Krystal Biotech has a 52 week low of $130.50 and a 52 week high of $382.54. The firm has a market cap of $9.21 billion, a price-to-earnings ratio of 41.79 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The business had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million.

Insiders Place Their Bets

In related news, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the transaction, the executive vice president owned 1,000 shares in the company, valued at $347,270. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock worth $8,243,923 over the last three months. Corporate insiders own 13.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

A number of institutional investors have recently bought and sold shares of the stock. Soleus Capital Management L.P. increased its holdings in shares of Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after purchasing an additional 481,200 shares during the period. Norges Bank purchased a new stake in shares of Krystal Biotech during the fourth quarter worth $70,159,000. William Blair Investment Management LLC increased its position in Krystal Biotech by 152.1% in the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after purchasing an additional 227,038 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Krystal Biotech by 2,078.9% in the 4th quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock valued at $54,147,000 after buying an additional 209,369 shares in the last quarter. Finally, UBS Group AG raised its position in Krystal Biotech by 970.8% during the fourth quarter. UBS Group AG now owns 159,595 shares of the company’s stock valued at $39,347,000 after acquiring an additional 177,922 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech News Summary

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Krystal reported diluted EPS of $1.79, above the $1.70 analyst consensus and up from $1.29 a year earlier. Net income rose to $54.8 million, while VYJUVEK revenue increased 24% year over year to $119.2 million. Krystal Biotech Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: VYJUVEK continues to show commercial momentum, with more than 730 reimbursement approvals and over 640 prescribers. The company remains on track to launch the therapy in Spain and Italy before year-end, and ended the quarter with a strong $1.1 billion in cash and investments. Krystal Biotech Announces Second Quarter 2026 Results
• Positive Sentiment: Investors also received several potential pipeline catalysts, including top-line KB803 corneal-abrasion data expected in the fourth quarter and additional clinical updates across respiratory, dermatology and oncology programs during the second half of 2026. Krystal Biotech Q2 2026 Earnings Call Transcript
• Neutral Sentiment: Management forecast 2026 non-GAAP R&D and SG&A expenses of $175 million to $195 million, reflecting continued investment in international commercialization and the broader pipeline. Krystal Biotech Outlines 2026 Operating Expense Range
• Negative Sentiment: Revenue of $119.22 million missed analysts’ $120.93 million estimate, tempering the impact of the EPS beat. Selling, general and administrative expenses increased to $39.9 million from $35.1 million, raising concerns about cost growth as the company expands. Krystal Biotech Shares Slide Despite Earnings Beat
• Negative Sentiment: European pricing and reimbursement discussions remain ongoing, with German negotiations potentially lasting into the second half of 2026 and French discussions extending into 2027. Those delays could postpone the full revenue contribution from overseas VYJUVEK launches.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.